医学
肺动脉高压
肺
肺病
流行病学
疾病
内科学
人口
重症监护医学
呼吸道疾病
心脏病学
环境卫生
作者
Oksana A. Shlobin,Yochai Adir,Joan Albert Barberá,Vincent Cottin,Sergio Harari,Étienne-Marie Jutant,Joanna Pepke‐Żaba,Hossein A. Ghofrani,Richard N. Channick
出处
期刊:The European respiratory journal
[European Respiratory Society]
日期:2024-08-29
卷期号:64 (4): 2401200-2401200
被引量:6
标识
DOI:10.1183/13993003.01200-2024
摘要
Pulmonary hypertension (PH) associated with chronic lung disease (CLD) is both common and underrecognised. The presence of PH in the setting of lung disease has been consistently shown to be associated with worse outcomes. Recent epidemiological studies have advanced understanding of the heterogeneity of this patient population and shown that defining both the specific type of CLD as well as the severity of PH ( i.e. deeper phenotyping) is necessary to inform natural history and prognosis. A systematic diagnostic approach to screening and confirmation of suspected PH in CLD is recommended. Numerous uncontrolled studies and one phase 3 randomised, controlled trial have suggested a benefit in treating PH in some patients with CLD, specifically those with fibrotic interstitial lung disease (ILD). However, other studies in diseases such as COPD-PH showed adverse outcomes with some therapies. Given the expanding list of approved pharmacological treatments for pulmonary arterial hypertension, developing a treatment algorithm for specific phenotypes of CLD-PH is required. This article will summarise existing data in COPD, ILD and other chronic lung diseases, and provide recommendations for classification of CLD-PH and approach to the diagnosis and management of these challenging patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI